Compare IMKTA & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMKTA | RAPT |
|---|---|---|
| Founded | 1963 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1994 | 2019 |
| Metric | IMKTA | RAPT |
|---|---|---|
| Price | $85.91 | $57.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $56.22 |
| AVG Volume (30 Days) | 129.2K | ★ 4.6M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,334,032,609.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.91 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $59.09 | $0.71 |
| 52 Week High | $90.49 | $58.02 |
| Indicator | IMKTA | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | 58.95 | 78.57 |
| Support Level | $68.58 | $32.00 |
| Resistance Level | $90.24 | N/A |
| Average True Range (ATR) | 2.65 | 0.09 |
| MACD | -0.66 | -0.79 |
| Stochastic Oscillator | 25.53 | 90.91 |
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.